Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Abliva: More Reasons to Believe

NE

Niklas Elmhammer

Redeye believes current valuation implies a too cautious view of Abliva’s project portfolio. Early evidence and positive regulatory feedback validate the development of lead candidate KL1333 in primary mitochondrial disease, an untapped orphan drug opportunity. A key element to further successful clinical development and hence rerating, in our opinion, is if Abliva can secure additional financing.

Disclosures and disclaimers